Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
| ▸ | BRS3 | P32247 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | NMBR | P28336 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933037 | 1.00 | CTSL (0.57) | CTSLTACR1BRS3OPRM1OPRD1 | |
| SCHEMBL25608899 | 0.94 | GHSR (0.57) | BRS3OPRM1OPRD1 | |
| SCHEMBL29564309 | 0.94 | GHSR (0.57) | BRS3OPRM1OPRD1 | |
| SCHEMBL26605057 | 0.91 | CTSL (0.54) | CTSLTACR1BRS3OPRM1OPRD1 | |
| SCHEMBL5178667 | 0.91 | CTSL (0.54) | CTSLTACR1BRS3OPRM1OPRD1 | |
| SCHEMBL29658156 | 0.89 | OPRD1 (0.57) | BRS3OPRM1OPRD1 | |
| SCHEMBL30358212 | 0.89 | ACE (0.54) | CTSLTACR1OPRM1OPRD1ACE | |
| SCHEMBL29867617 | 0.88 | EDNRA (0.53) | CTSLTACR1OPRM1OPRD1ACE | |
| SCHEMBL29565336 | 0.87 | GHSR (0.58) | BRS3OPRM1OPRD1 | |
| SCHEMBL30052868 | 0.87 | KDM4E (0.60) | CTSLOPRM1OPRD1ACENMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004715-A | — | — | None | — | — | JP | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-1436317-A1 | MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0779894-B1 | ELECTROPHILIC POLYETHYLENE OXIDES FOR THE MODIFICATION OF POLYSACCHARIDES, POLYPEPTIDES (PROTEINS) AND SURFACES | BIOSURFACE ENG TECH INC (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003024995-A1 | MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2003-03-27 | — | — | WO | disclosed |
| EP-0779894-A4 | ELECTROPHILIC POLYETHYLENE OXIDES FOR THE MODIFICATION OF POLYSACCHARIDES, POLYPEPTIDES (PROTEINS) AND SURFACES | SURFACE ENG TECH (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5650234-A | FOR USE AS MEMBRANE COATINGS | SURFACE ENGINEERING TECHNOLOGIES, DIVISION OF INNERDYNE, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0779894-A1 | ELECTROPHILIC POLYETHYLENE OXIDES FOR THE MODIFICATION OF POLYSACCHARIDES, POLYPEPTIDES (PROTEINS) AND SURFACES | SURFACE ENGINEERING TECHNOLOGIES DIVISION OF INNERDYNE, INC. (US) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007670-A9 | ELECTROPHILIC POLYETHYLENE OXIDES FOR THE MODIFICATION OF POLYSACCHARIDES, POLYPEPTIDES (PROTEINS) AND SURFACES | — | 1996-05-23 | — | — | WO | disclosed |
| WO-1996007670-A1 | ELECTROPHILIC POLYETHYLENE OXIDES FOR THE MODIFICATION OF POLYSACCHARIDES, POLYPEPTIDES (PROTEINS) AND SURFACES | SURFACE ENGINEERING TECHNOLOGIES, DIVISION OF INNERDYNE, INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| JP-H024715-A | NUTRITIVE TRANSFUSION SOLUTION COMPOSITION OF AMINO ACID NOT CONTAINING STABILIZER | MORISHITA PHARMACEUT CO LTD | 1990-01-09 | — | — | JP | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSL 108/4885TACR1 2068/4885BRS3 1616/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSL 14/4885TACR1 374/4885BRS3 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.